Sentences with phrase «immune cell therapy»

This is the first dataset, where we tried to capture all known industry immune cell therapy developers.

Then immunotherapy firm Juno Therapeutics shook hands with gene - editing start - up Editas to create anticancer immune cell therapies; Vertex Pharmaceuticals and Crispr Therapeutics, another start - up, inked an agreement that could be valued at $ 2.6 billion; while Regeneron Pharmaceuticals formed a patent licence agreement with ERS Genomics, which holds the rights to the foundational Crispr intellectual property from Emmanuelle Charpentier, one of the Crispr pioneers.

«If immune cell therapies for cancer or autoimmune diseases (like rheumatoid arthritis, for example) are going to be safe and effective alternatives to more traditional medications, we must gain control over the activity of the cells to reduce risks of toxicity to the patient,» said Roybal.

His laboratory harnesses the tools of synthetic and chemical biology to engineer the immune cell therapies for cancer and autoimmunity of the future.

Not exact matches

The Food and Drug Administration (FDA) on Tuesday gave Swiss drug giant Novartis a second approval for its pioneering CAR - T cancer therapy, which uses patients» own immune cells (re-engineered outside the body and then replicated) to destroy blood cancers.

Basically, CAR - T therapy involves taking a patient's own immune «killer» T - cells, inserting new genetic code into those cells which turn them into cancer - hunters that can home in on malignant B - cells (another kind of immune cell), and then pumping these specialized leukemia - busting cells back into the patient.

The treatment is a type of so - called CAR T - cell therapy — taking a patient's own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient.

Gilead subsidiary Kite Pharma (which the biotech giant scooped up ahead of the FDA's approval for Yescarta, a treatment that reengineers patients» immune cells to fight cancer) will have access to Sangamo's platform technology, which could be used to create various types of cancer cell therapies.

CAR - T cell therapy is a form of immunotherapy, a rapidly developing cancer treatment that uses patients» own immune cells to attack tumors.

Bellicum is among the flurry of biotechs investing heavily into cell therapies such as experimental chimeric antigen receptor T - cell (CAR - T) treatments for cancer (this is the next - gen treatment that involves reprogramming immune cells to become cancer killers and has shown promise in blood cancers, which Bellicum specializes in).

Swiss pharmaceutical giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

Santa Monica, California - based Kite is developing chimeric antigen receptor T - cell therapy, known as a CAR T, which harnesses the body's own immune cells to recognize and attack malignant cells.

With major clinical successes in areas such as CAR - T, gene therapy, immune - oncology, cell therapy and gene editing, many see 2017 as the year that biotech really came of age.

For example, we've seen new discoveries in health care recently, especially in immuno - oncology therapies, which help the immune systems of cancer patients recognize and destroy cancerous cells.

During the sessions, U.S. and Cuban scientists explored such topics as the molecular mechanisms cancer cells employ to evade the body's immune system, new tools to image and manipulate that system, and ways to rethink how such therapies can best be deployed to reach patients where they receive health services.

A group of the nation's leading cancer research scientists and their Cuban counterparts are exploring how to advance cancer therapy, diagnosis, and prevention, including the use of immunotherapy to harness the body's immune systems to attack and eliminate cancer cells.

A type of immune therapy known as PD - 1 blockade controlled cancer in 77 percent of patients with defects in DNA mismatch repair — the system cells use to spell - check and fix errors in DNA (SN Online: 10/7/15).

A transformative cancer therapy based on modified immune cells has lured doctors, companies, and patients alike, but many are hitting a frustrating roadblock: generating enough of these chimeric antigen receptor (CAR)- T cells to meet surging demand.

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

«Current therapies in clinical trials are focused on targeting genetic changes in tumors and helping to boost one's immune system to fight the cancer cells.

In the GD2 CAR - T treated animals, the residual cancer cells did not express GD2, suggesting that these remaining cells were not vulnerable to the immune therapy and might be able to cause the cancer to recur.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

Because the CAR - T cells do not eradicate all cancer cells, the researchers think the immune therapy will need to be combined with other treatments.

Ten years after infection with HIV, a typical person has progressed to where tens if not hundreds of thousands of copies of the virus can be found in a single milliliter of their blood and more than three quarters of their CD4 immune cells are destroyed, if they have not started drug therapy.

Antibodies and T cells against the protein could cause the immune system to attack cells carrying it, making gene therapy ineffective.

And early stage startup Neochromosome, which includes Boeke, intends to raise money to design synthetic chromosomes for medicine that could be used in an off - the - shelf universal cell line in cell therapies and transplants with minimal risk of rejection from the immune system.

«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.

EMD Serono, Kirschbaum says, «focuses on the development of targeted cancer therapies on three therapeutic platforms: targeting the tumor cell, the tumor environment, and the immune system.»

Researchers are developing many different versions of CAR - T cell therapies, but the basic premise is the same: Doctors remove a patient's T cells (immune system cells that attack invaders) from a blood sample and genetically modify them to produce artificial proteins on their surfaces.

Oral immunotherapy for peanut allergy induces early, distinct changes in immune T - cell populations that potentially may help researchers determine which people will respond well to the therapy and which immune mechanisms are involved in the response, a new study suggests.

Eye diseases — such as age - related macular degeneration, as well as a genetic condition called Stargardt's macular dystrophy that afflicts young people — are considered excellent candidates for stem cell therapy because the eye is an immune - privileged site, meaning transplanted cells are not as likely to be rejected as foreign compared with transplants elsewhere.

HIV also hides in cells and continues to undermine the host's immune system despite antiretroviral therapy that has improved the outlook of those with AIDS.

Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).

A phase 3 trial of lenalidomide / dexamethasone with elotuzumab (Empliciti ™), an antibody therapy that attacks myeloma cells directly and spurs the immune system to launch an attack of its own.

Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.

With additional genome tinkering to avoid rejection by the immune system, they could be used clinically as a universal stem cell therapy.

Researchers have designed a nanoparticle - based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow.

Wistar scientists have previously shown that age - related changes in the tumor microenvironment — or the surrounding area where tumor cells crosstalk with normal and immune cells — can drive melanoma progression and therapy resistance.

A new wave of potential immune therapies aims to target the network of complex sugars that coat cancer cells, Esther Landhuis reported in «Cancer's sweet cloak» (SN: 4/1/17, p. 24).

«Because we observed microbial effects mainly in the gut, we believe that a microbe - based therapy would avoid the collateral damage seen with drugs that wipe out classes of immune cells across the body,» said Benoist, a professor of microbiology and immunobiology at HMS.

The team also compared the animals» responses to the therapy's effects in laboratory cell samples and found that in vitro studies did not predict how well the viral therapy and immune response would fight tumor cells in vivo.

Dr. Cripe and his colleagues at The Ohio State University, the University of Pittsburgh School of Medicine and Cincinnati Children's Hospital Medical Center tested how well the oncolytic viral therapy — a cancer - killing form of the herpes simplex virus, called oHSV — infected and killed tumor cells in mice with and without a healthy immune system.

Epigenetic therapies are thought to work in two ways to fix these errors in cancer cells — by correcting the «position» of the gene switches and by making the cell appear as though it's infected by a virus, triggering the immune system.

2011: Another success makes headlines: David Porter and Carl June report that immune cells modified with gene therapy had cured two terminal leukemia patients of their cancer.

According to Dr. Cripe, the study suggests that some patients could respond to therapy even if their tumors aren't very infectable by the virus, provided their immune systems were stimulated by the viral therapy to attack the tumor cells.

Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the immune system to attack cancer cells as the foreign invaders they are — has so far had limited success, primarily because the immune system often can't destroy the cancer cells.

However, ChABC gene therapy decreased the presence of these cells and increased the presence of other immune cells called M2 macrophages that help to reduce inflammation and enhance tissue repair.

The researchers were able to reverse these epigenetic changes with the use of an FDA - approved drug, forcing the cancer cells out of hiding and potentially making them better targets for the same immune therapy that in the past may have failed.

«We haven't held out much hope for immune therapy to work in them because before you can enter cancer cells to knock them down, you have to be able to get inside.